To the Editor, While treatment of relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL) remains a significant challenge, those with T-cell ALL (T-ALL) have particularly poor outcomes. Patients with R/R T-ALL and T-cell lymphoblastic lymphoma (T-LBL) have a median overall survival (mOS) of approximately 6 months.1 Nelarabine is the only Food and Drug Administration (FDA) approved therapy for R/R T-ALL.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile